Expert Review Logo
Welcome Guest user | Log in | Athens Login | Shibboleth Login | Register
Resources
Register
For Authors
For Librarians
For Advertisers
Services
Subscriptions/Pricing
Reprints
Advertising
Press Releases/News
Help
Downloads/Links
2008/9 Catalogue
Library Recommendation
Summary
November 2005, Vol. 2, No. 6, Pages 699-711 , DOI 10.1586/17434440.2.6.699
(doi:10.1586/17434440.2.6.699)

Review
Central venous access devices in patients with hemophilia
Leonard A Valentino & Mukesh Kapoor
Author for correspondence



Hemophilia is a hereditary disorder in which the major clinical manifestation is bleeding into the joints, muscles, internal organs and the CNS, often without any obvious trauma. Bleeding can be fatal as in the case of CNS hemorrhage, or severely debilitating following repeated bleeding into joints that results in crippling arthritis. Treatment for hemophilia includes the intravenous administration of clotting factor concentrates to replace the missing or defective protein. Venous access is therefore critical to the treatment of hemophilia and the prevention of complications due to bleeding. According to the US Centers for Disease Control and Prevention, approximately half of patients less than 16 years of age and one-third of all patients with hemophilia receive regular prophylactic injections of clotting factor concentrates. Prophylaxis, or the regular scheduled administration of antihemophilic factor concentrate, is effective in preventing bleeding. Among those patients with severe disease, in the absence of prophylaxis, approximately 13 bleeds, including nine joint hemorrhages, occur annually. In contrast, when prophylaxis is administered, the annual number of total and joint bleeds decreases to five and three, respectively. One of the major barriers to the more wide-spread use of prophylaxis is venous access. While peripheral venipuncture remains the first choice for venous access, central venous access devices are frequently used to facilitate repeated and/or urgent administration of clotting factor concentrates. The advantages of central venous access devices are well recognized in certain treatment regimens such as prophylaxis and immune tolerance therapy, as well as certain patient groups such as young children in whom venipuncture is often difficult and traumatic, and adults with scarred veins. Central venous access devices also allow earlier commencement of both home treatment and prophylaxis. The goal of this review is to discuss the different types of central venous access devices and their role in the management of hemophilia to provide practitioners that care for patients with hemophilia with the necessary information to make sound therapeutic recommendations to their patients.

Full Text PDF (167 KB) PDF Plus (270 KB)

Cited by

M. R. JENG, M. O’BRIEN, W. WONG, J. ZOLAND, J. LEA, N. TANG, B. GLADER. (2009) Monthly recombinant tissue plasminogen activator administration to implantable central venous access devices decreases infections in children with haemophilia. Haemophilia
Online publication date: 1-Aug-2009.
CrossRef
Manasvi Upadhyaya, Michael Richards, Sarah Buckham, B. R. Squire. (2009) Long-term results of central venous access devices in children with haemophilia. Pediatric Surgery International 25:6, 503-506
Online publication date: 1-Jul-2009.
CrossRef
C. E. NEUNERT, K. L. MILLER, J. M. JOURNEYCAKE, G. R. BUCHANAN. (2008) Implantable central venous access device procedures in haemophilia patients without an inhibitor: systematic review of the literature and institutional experience. Haemophilia 14:2, 260-270
Online publication date: 1-Apr-2008.
CrossRef
E. C. RODRIGUEZ-MERCHAN, L. VALENTINO, M. QUINTANA. (2007) Prophylaxis and treatment of chronic synovitis in haemophilia patients with inhibitors. Haemophilia 13:s3, 45-48
Online publication date: 1-Dec-2007.
CrossRef
Kimo C. Stine, Dixie Shrum, David L. Becton. (2007) Use of FEIBA for Invasive or Surgical Procedures in Patients With Severe Hemophilia A or B With Inhibitors. Journal of Pediatric Hematology/Oncology 29:4, 216-221
Online publication date: 1-May-2007.
CrossRef
L. A. VALENTINO. (2007) FEIBA prophylaxis for patients with haemophilia and inhibitors. Haemophilia 12:s5, 26-31
Online publication date: 1-Jan-2007.
CrossRef

Users who read this article also read:

Vancomycin resistance: are there better glycopeptides coming?
Peter K Linden
Expert Review of Anti-infective Therapy, Dec 2008, Vol. 6, No. 6, Pages 917-928.
Summary | Full Text | PDF (379 KB) | PDF Plus (452 KB) | Add to Favorites | Related 
Key biological issues in contact lens development
Seana M McGlinchey, Colin P McCoy, Sean P Gorman, David S Jones
Expert Review of Medical Devices, Sep 2008, Vol. 5, No. 5, Pages 581-590.
Summary | Full Text | PDF (786 KB) | PDF Plus (814 KB) | Add to Favorites | Related 
Community-acquired pneumonia: is it time to shorten the antibiotic treatment?
Silvano Esposito, Marco Fiore
Expert Review of Anti-infective Therapy, Dec 2007, Vol. 5, No. 6, Pages 933-938.
Summary | Full Text | PDF (93 KB) | PDF Plus (169 KB) | Add to Favorites | Related 
The use of fluoroquinolones in children: recent advances
Ioanna M Velissariou
Expert Review of Anti-infective Therapy, Oct 2006, Vol. 4, No. 5, Pages 853-860.
Summary | Full Text | PDF (380 KB) | PDF Plus (459 KB) | Add to Favorites | Related 
 

Prev. Article | Next Article
View/Print PDF (167 KB)
View PDF Plus (270 KB)
Add to favorites
Email to a friend
TOC Alert | Citation Alert What is RSS?

 
 
Quick Search
for 
Authors:
Leonard A Valentino
Mukesh Kapoor
Keywords:
devices
hemophilia
infusion therapy
veins
venous access


Expert Reviews Ltd, Unitec House, 2 Albert Place, London, N3 1QB, UK
Business Office: Tel +44 (0)20 8371 6080 · Fax +44 (0)20 8371 6099 
Editorial Office: Tel +44 (0)20 8371 6090 · Fax +44 (0)20 8343 2313
We welcome your Feedback. See our Privacy Statement and Terms and Conditions.